Log In Sign up
The largest database of trusted experimental protocols

Rapamycin

Manufactured by Axon Medchem
Visit Supplier

Rapamycin is a macrolide compound that functions as an immunosuppressant and anti-proliferative agent. It is a product of the bacterium Streptomyces hygroscopicus.

Automatically generated - may contain errors

Lab products found in correlation

Pimozide, by Merck Group (1 mentions) Ruxolitinib, by Merck Group (1 mentions) Ly294002, by Cell Signaling Technology (1 mentions) Mk2206, by Axon Medchem (1 mentions) Azd6244, by Axon Medchem (1 mentions) Gdc 0941, by Axon Medchem (1 mentions) Lorlatinib, by Pfizer (1 mentions) Ly3009120, by Selleck Chemicals (1 mentions) Trametinib, by Axon Medchem (1 mentions)

2 protocols using rapamycin

1

Selective Kinase Inhibitors Panel

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following inhibitors were obtained from Selleck Chem (Munich, Germany, unless otherwise indicated): JAK inh 1 (Merck Millipore, Billerica, MA, USA; #420099), ruxolitinib (#S1378), pimozide (Sigma-Aldrich, Zwijndrecht, The Netherlands; #P1793), Ly294002 (Cell Signaling Technology, Leiden, The Netherlands; #9901), MK-2206 (#S1078), rapamycin (#S1039), CI-1040 (Axon Medchem, Groningen, The Netherlands; #1368), AZD6244 (#S1008) and GDC-0941 (#S1065).
Canté-Barrett K., Spijkers-Hagelstein J.A., Buijs-Gladdines J.G., Uitdehaag J.C., Smits W.K., van der Zwet J., Buijsman R.C., Zaman G.J., Pieters R, & Meijerink J.P. (2016). MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia. Leukemia, 30(9), 1832-1843.
+ Open protocol
+ Expand
2

Evaluation of Targeted Cancer Therapies

Check if the same lab product or an alternative is used in the 5 most similar protocols
Lorlatinib, ceritinib, trametinib, rapamycin and pictilisib were purchased from Axon Medchem (#Axon2600, #Axon224, #Axon1761, #Axon2069, #Axon1377). Lorlatinib was given from Pfizer for in vivo studies with the NBLW-R. LY3009120 was bought from Selleck Chemicals (#S7842).
Berlak M., Tucker E., Dorel M., Winkler A., McGearey A., Rodriguez-Fos E., da Costa B.M., Barker K., Fyle E., Calton E., Eising S., Ober K., Hughes D., Koutroumanidou E., Carter P., Stankunaite R., Proszek P., Jain N., Rosswog C., Dorado-Garcia H., Molenaar J.J., Hubank M., Barone G., Anderson J., Lang P., Deubzer H.E., Künkele A., Fischer M., Eggert A., Kloft C., Henssen A.G., Boettcher M., Hertwig F., Blüthgen N., Chesler L, & Schulte J.H. (2022). Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells. Molecular Cancer, 21, 126.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!